Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the registration clinical trial application for GenSci117 inhalation powder, developed by its subsidiary Changchun Genescience Pharmaceutical Co., Ltd. (“GenSci”), has been accepted by China’s National Medical Products Administration (NMPA) — advancing a novel inhaled small interfering RNA (siRNA) drug targeting matrix metalloproteinase 7 (MMP7) for the treatment of idiopathic pulmonary fibrosis (IPF).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Action | Acceptance of registration clinical trial application |
| Product | GenSci117 inhalation powder |
| Modality | Inhaled small interfering RNA (siRNA) |
| Target | Matrix metalloproteinase 7 (MMP7) |
| Drug Classification | Class 1 chemical drug |
| Intended Indication | Idiopathic pulmonary fibrosis (IPF) |
| Announcement Date | 5 Nov 2026 |
| Developer | Changchun Genescience Pharmaceutical Co., Ltd. (GenSci), subsidiary of Changchun High & New Technology Industries (Group) Inc. |
Drug Profile & Mechanism of Action
- Molecule: GenSci117 — a novel inhaled siRNA drug candidate, classified as a Class 1 chemical drug in China.
- Target: MMP7 (matrix metalloproteinase 7), an enzyme mainly secreted by epithelial‑derived cells and activated macrophages that, under pathological conditions, drives fibrosis, tumor invasion, and inflammation.
- Delivery Platform: Built on GenSci’s extrahepatic siRNA delivery platform GPODS, enabling lung‑targeted RNAi beyond conventional liver‑directed approaches.
- RNAi Mechanism: GenSci117 mediates targeted delivery of siRNA into target cells, where the siRNA specifically recognizes and promotes degradation of MMP7 mRNA through the RNA interference (RNAi) mechanism — inhibiting MMP7 expression, reducing MMP7 protein production and accumulation, and ultimately attenuating its pro‑fibrotic effects.
- Dosing Convenience: The product is expected to achieve a dosing interval of once every two months, which can significantly improve dosing convenience and thereby enhance patient compliance.
Therapeutic Area Background – Idiopathic Pulmonary Fibrosis
- Disease Burden: IPF is a chronic, progressive, and ultimately fatal fibrotic lung disease characterized by irreversible decline in lung function; treatment options that slow progression remain limited.
- MMP7 Rationale: As an enzyme implicated in fibrotic remodeling and secreted by key pathogenic cell types in the fibrotic lung, MMP7 represents a biologically grounded target for disease‑modifying intervention.
- Inhaled Route Advantage: Direct pulmonary delivery of siRNA positions the drug at the site of disease, leveraging the GPODS extrahepatic delivery platform to achieve local target engagement in lung tissue.
- Compliance Gap: Current IPF therapies typically require daily oral dosing with tolerability challenges; a once‑every‑two‑month inhaled regimen would mark a substantial convenience improvement if realized in development.
- Stage Note: This is an early clinical‑stage milestone; efficacy and safety data from the registered clinical trial have not yet been disclosed.
Market Impact & Outlook
- RNAi Beyond the Liver: GenSci117 showcases the extension of siRNA therapeutics into extrahepatic, inhaled formats — one of the field’s most significant technical frontiers, enabled by the in‑house GPODS platform.
- First‑in‑Class Potential: An inhaled siRNA targeting MMP7 for IPF represents a novel mechanism and route in a therapeutic area dominated by small‑molecule antifibrotics, differentiating GenSci’s approach at the source of fibrotic signaling.
- Pipeline Validation: NMPA acceptance of the registration clinical trial application marks a concrete regulatory checkpoint for GenSci’s RNAi platform and strengthens the parent group’s innovation portfolio.
- Chronic‑Disease Economics: If the bi‑monthly dosing expectation holds, the regimen could materially improve adherence in a chronic indication where compliance directly affects long‑term outcomes.
- Next Catalysts: Trial initiation and enrollment, first‑in‑patient safety and pharmacodynamic data on MMP7 suppression, and subsequent registrational pathway milestones with the NMPA.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, regulatory progression, dosing expectations, and therapeutic potential of GenSci117 inhalation powder. Acceptance of a registration clinical trial application does not guarantee trial outcomes or future marketing approval. Actual results may differ due to risks including clinical trial conduct and enrollment, safety and efficacy findings, RNAi delivery performance in humans, regulatory review requirements, and competitive dynamics in the IPF treatment landscape.-Fineline Info & Tech
